ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Accounts Receivable, Related Parties
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Accounts Receivable, Related Parties of $8.47 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-07-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2021-05-05
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable, related parties for the quarter ending 2020-06-30 was -$117.08M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable, related parties for the quarter ending 2020-03-31 was $125.55M.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month |
|---|---|---|
| 2020-06-30 | -$117.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $8.47M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $125.55M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |